Emai:marketing@videisimo.net
业务咨询专线:400-780-8018
Tel: +1(626)986-9880(U.S. - West Coast)
0044 7790 816 954 (Europe)
Email: marketing@medicilon.com
地址:上海市浦东新区川大路585号
邮编:201299
电话:+86 (21) 5859-1500(总机)
传真:+86 (21) 5859-6369
© 2023 上海AG真人国际(中国)官方官网生物医药股份有限公司 保留所有权利 沪ICP备20778367号-3
业务咨询
中国:
Email: marketing@videisimo.net
业务咨询专线:400-780-8018
(仅限服务咨询,其他事宜请拨打川沙总部电话)
川沙总部电话: +86 (21) 5859-1500
海外:
+1(626)986-9880(U.S. - West Coast)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
Ulotaront (SEP-363856) is a TAAR1 agonist with 5-HT1A agonist activity currently in clinical development for the treatment of Schizophrenia. Ulotaront exhibits rapid absorption, greater than 70% bioavailability, and good penetration across the blood–brain barrier in preclinical species. The distribution of Ulotaront to rat brain was conducted at Medicilon/MPI Preclinical Research. Ulotaront monkey plasma PK was conducted at Medicilon/MPI Preclinical Research.
Reference: